HealthcareMid capRs 16,115 crRs 20.9 cr traded a day
Close on 10 September 2026
508.35
−1.04%
52-week range66% of the way up
406.55560.70
Market cap
16,115 cr
P/E (TTM)
87.1×
industry 45×
EPS (TTM)
5.84
Revenue YoY
+26.0%
Q1 FY27
Profit YoY
+44.6%
Net margin
9.0%
+1.2pt vs a year ago
Growth trend
+3.4pt
vs last quarter’s YoY
1 month
-0.6%
Below 52w high
10.3%
RSI (14)
57
Daily swing
2.5%
average true range
Volume
0.3×
vs 20-day average
Traded
Rs 21 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
Key metrics
each ranked against every stock scanned tonight
Above the 200-day average
Around the median
+8.1%
One-year return
Above the median
+11.6%
Return on capital employed
n/a
Debt to equity
n/a
Profitable quarters, last four
of the last four reported
4 of 4
Cash conversion
cash from operations against reported profit
n/a
Revenue growth, year on year
latest reported quarter
+26.0%
Below the 52-week high
from the highest close of the year
-9.3%
1 week
−0.61%
1 month
−0.61%
3 months
+15.72%
6 months
+17.14%
1 year
+11.63%
The read
written from the numbers on this page
The evidence leans constructive6 supporting, 2 against, 1 worth knowing
Supporting
trading 8% above its 200-day average
up 12% over twelve months
matches profit jumped this quarter, which has beaten the market by +0.65 points over 20 sessions across 84,077 past signals
3 of the scans it matches have a positive measured record
revenue grew 26% year on year in the quarter ending 30 June 2026
net margin has widened from 7.3% to 9.0% across four quarters
Against
1 of the scans it matches has historically underperformed the market
priced at 87× earnings against an industry median of 45× — 95% above its peers
Worth knowing
the 5 scans it matches come from only 2 families — one signal wearing several hats rather than several signals
What would change this read: a close below 470, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working4
Net profit rose 44.6% year on year, from Rs 38 cr to Rs 55 cr.
+44.6%Rs 38 crRs 55 cr
Revenue rose 26.0% year on year, from Rs 487 cr to Rs 614 cr.
+26.0%Rs 487 crRs 614 cr
Profit grew faster than revenue, +44.6% against +26.0%.
+44.6%+26.0%
Trading 8.1% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.
+8.1%
Needs watching
Nothing on this side tonight — not in the filings and not in the price.
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 3 of these 3 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
5 of 47 matched on 10 Sep
AGARWALEYE matches 5 of the 47 scans today, across 2 different kinds of evidence. Note how few kinds of evidence that is: several scans in one family are one signal wearing several hats, not several signals.
AGARWALEYE trades at 87× trailing earnings, close to its median of 90× over this window. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically +0.01pt vs the market over the next 5 sessions (n=17,202) · AGM / EGM filings were typically +0.17pt vs the market over the next 5 sessions (n=8,423) · Analyst call filings were typically +0.11pt vs the market over the next 5 sessions (n=4,339)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 26% against the same quarter a year earlier
profit rose 45% year on year
net margin widened from 8.9% to 9.0%
revenue rose in 4 of the last 4 quarters
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
614
75
55
1.43
9.0%
Q4 FY26
31 Mar · consolidated
564
77
50
1.25
8.9%
Q3 FY26
31 Dec · consolidated
530
65
44
1.07
8.2%
Q2 FY26
30 Sep · consolidated
499
54
36
0.94
7.3%
Q1 FY26
30 Jun · consolidated
487
54
38
0.95
7.8%
Q4 FY25
31 Mar · consolidated
460
59
43
1.04
9.2%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+1.7%
Versus 200-day average+8.1%
Below 52-week high-9.3%
Above 52-week low+25.0%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)57.1
Higher closes in last 53 of 5
Six-month return+17.14%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)2.53%
Volume versus 20-day0.3x
Median daily turnoverRs 20.9 cr
Peers
Healthcare · 68 classified companies
AGARWALEYE trades at 87.1× trailing earnings against an industry median of 44.7× across 65 other classified companies in its industry — more expensive than them, by 95%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
Session
Scans
Which
28 Aug
2
Uptrend taking a breather, Oversold, but trend intact